Krieger S |
Multiple sclerosis therapeutic pipeline: opportunities and challenges. |
|
Mt. Sinai J. Med. |
pmid:21425264
|
Hussar DA and Zimmerman DE |
New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate. |
|
J Am Pharm Assoc (2003) |
pmid:21247838
|
Ubai T et al. |
FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. |
|
Anticancer Res. |
pmid:17352219
|
Yopp AC et al. |
Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. |
|
Clin Transplant |
pmid:17100731
|
Tedesco-Silva H et al. |
FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. |
|
Clin Transplant |
pmid:19719728
|
Pin D et al. |
An emulsion restores the skin barrier by decreasing the skin pH and inflammation in a canine experimental model. |
|
J. Comp. Pathol. |
pmid:24975893
|
Suleiman M et al. |
FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. |
|
Transplant. Proc. |
pmid:15808648
|
Yanagawa Y et al. |
FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-cell infiltration into grafts. |
|
Transplant. Proc. |
pmid:10083548
|
Suzuki T et al. |
Dose-dependent study of a novel immunosuppressant, FTY720, with the canine renal allograft transplantation model. |
|
Transplant. Proc. |
pmid:10083540
|
Kunikata S et al. |
Immunosuppressive action of FTY720 for renal allograft a rat model. |
|
Transplant. Proc. |
pmid:10083517
|